December 15, 2017
Geelong, Australia – Prevatex Pty Ltd an emerging life sciences company focussed on developing and bringing to market next generation probiotics to restore and maintain a healthy maternal microbiome during pregnancy, is pleased to announce that it has completed a limited capital raise to private investors.
“This capital raise, from founders and other sophisticated investors will enable us to progress several key projects towards our goal of producing and commercializing novel probiotics to optimise the maternal microbiome. This has been associated with positive outcomes for infants in terms of both reduced allergies and improved behaviour” said Dr Greg Collier, PhD, Executive Chairman of Prevatex.
“Over coming months we will commence studies to optimise the isolation and growth of proprietary strains of Prevatella copri, working towards safety trials in humans in 2020.”